London, UK; Brentwood, TN, US: 19 March 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that, on 16 March 2007, a notification of interest in
the ordinary share capital of the Company was received from AXA Investment
Managers Limited on behalf of AXA S.A. in accordance with the Transparency
Obligations Directive. Details of the interest notified are as follows:
